Aetna · Tirzepatide · US health-plan appeal rights

Tirzepatide denied as experimental or investigational by Aetna?

Q: How long do I have to appeal a Aetna Tirzepatide denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

An experimental denial requires the appeal to cite the FDA approval (if any), peer-reviewed phase III data, and the recognised specialty-society guideline that supports the treatment for your indication.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-06-01

Policy data current as of 2026-05-24

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

HbA1c ≥6.5% per CVS Caremark form 5496-C.

Source policy: Aetna tirzepatide [t2dm] structured rules seed

What works in the appeal

See structured rules. Use plan-medical-necessity override + named guideline citations + step-therapy contraindications where applicable.

The Aetna angle on Tirzepatide

## Aetna Denying Tirzepatide as "Experimental/Investigational" — Dismantling the E/I Label

An Aetna "experimental and investigational" denial on tirzepatide (Mounjaro/Zepbound) is almost always procedurally defective. Tirzepatide is FDA-approved for type 2 diabetes (May 2022) under Mounjaro and for chronic weight management (November 2023) under Zepbound. The E/I label exists in Aetna's nomenclature for unproven uses — it cannot lawfully attach to an on-label indication backed by SURPASS-1 through SURPASS-5 and SURMOUNT-1/2 pivotal trials. The denial typically signals that the reviewer mis-coded the request or pulled the wrong CPB.

The controlling documents. Aetna's pharmacy benefit for tirzepatide is administered through CVS Caremark, not Aetna medical. The operative criteria sit in CVS Caremark prior authorization form 5496-C (Mounjaro, T2DM), which requires HbA1c ≥6.5% plus documented metformin trial or contraindication. For weight management, Aetna CPB 0039 (Weight Reduction Medications and Programs) and CPB 0595 (Obesity Surgery) govern Zepbound. Aetna Clinical Policy Bulletin 0438 (Diabetes Mellitus: Treatment) explicitly lists tirzepatide as medically necessary for T2DM meeting CPB criteria — flatly contradicting any E/I designation for that indication.

ERISA burden-shifting. Under Pinto v. Aetna Life Insurance Co. (10th Cir. 2014), once a claimant produces FDA labeling and peer-reviewed evidence supporting the requested use, the plan carries the burden of producing the specific scientific evidence on which its E/I determination rests. A boilerplate "experimental" denial without citation to the literature reviewed violates 29 CFR §2560.503-1(g)(1)(v)(B), which requires disclosure of the specific scientific or clinical judgment underlying the adverse benefit determination. Demand the underlying clinical review and the reviewer's credentials in writing.

The wrong-bucket problem. If you submitted Zepbound through medical benefit, Aetna's medical reviewer may have applied an obesity-drug exclusion rather than CPB 0039 criteria and reflexively labeled it E/I. Re-route through CVS Caremark pharmacy benefit using the correct PA form — form 5496-C for T2DM (Mounjaro), Caremark's weight-management PA pathway for Zepbound. Self-funded ERISA plans frequently carve out anti-obesity medications entirely; if so, the denial should read "plan exclusion," not "experimental," and that mis-labeling is itself reversible error.

Tactical closer: Open the appeal with one sentence: "Tirzepatide is FDA-approved under NDA 215866 (Mounjaro, 2022) and NDA 217806 (Zepbound, 2023); Aetna CPB 0438 expressly endorses it for T2DM meeting criteria — the E/I determination is facially erroneous." Attach the FDA approval letters, the CPB 0438 excerpt, the patient's HbA1c lab (≥6.5%), and the metformin trial/intolerance documentation. File concurrently with the state Department of Insurance (or DOL EBSA for ERISA self-funded plans) — the parallel complaint typically triggers a same-week reversal.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other insurers on Tirzepatide

Other denial reasons for Aetna Tirzepatide

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as not FDA-approved for this use

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-06-01. Editorial standards: denialhelp.com/authors.